Related references
Note: Only part of the references are listed.Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus A case report
In Hee Lee et al.
MEDICINE (2020)
SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate
Michael S. Balzer et al.
BIOMOLECULES (2020)
SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
Ying Zhou et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Dapagliflozin as a cause of acute tubular necrosis with heavy consequences: a case report
Christos Pleros et al.
CEN CASE REPORTS (2018)
Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
B. Komoroski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Share Paper
